Fosmidomycin for malaria
Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2002-12, Vol.360 (9349), p.1941-1942 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1942 |
|---|---|
| container_issue | 9349 |
| container_start_page | 1941 |
| container_title | The Lancet (British edition) |
| container_volume | 360 |
| creator | Missinou, Michel A Borrmann, Steffen Schindler, Andreas Issifou, Saadou Adegnika, Ayola A Matsiegui, Pierre-Blaise Binder, Ronald Lell, Bertrand Wiesner, Jochen Baranek, Thomas Jomaa, Hassan Kremsner, Peter G |
| description | Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more. |
| doi_str_mv | 10.1016/S0140-6736(02)11860-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2069928761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673602118605</els_id><sourcerecordid>2069928761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-25eaaa8126ca5497f50b42af20f45e584a2d9c330ec7e3d6e88acdddfb5bc8d43</originalsourceid><addsrcrecordid>eNqF0D1LAzEYwPEgiq3V3UUpiqDDad4vmUSKVaHgoIJbyOUFUnp3NWmFfnvT9rCTOGX5PU-SPwBnCN4iiPjdG0QUFrwk_BriG4QEhwXbA31ES1owWn7ug_4v6YGjlKYQQsohOwQ9hKkkmJM-OB23qQ62rVcmNEPfxmGtZzoGfQwOvJ4ld9KdA_AxfnwfPReT16eX0cOkMJTyRYGZ01oLhLnRjMrSM1hRrD2GnjLHBNXYSkMIdKZ0xHInhDbWWl-xyghLyQBcbvfOY_u1dGmhpu0yNvlKhSGXEouSo6wu_lJICil4_kxGbItMbFOKzqt5DLWOK4WgWkdTm2hqXURBrDbRFMtz593yZVU7u5vqKmVw1QGdjJ75qBsT0s5RIkkpeHb3W-dysO_gokomuMY4G6IzC2Xb8M9TfgAi7IZJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198986263</pqid></control><display><type>article</type><title>Fosmidomycin for malaria</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EBSCOhost Business Source Complete</source><creator>Missinou, Michel A ; Borrmann, Steffen ; Schindler, Andreas ; Issifou, Saadou ; Adegnika, Ayola A ; Matsiegui, Pierre-Blaise ; Binder, Ronald ; Lell, Bertrand ; Wiesner, Jochen ; Baranek, Thomas ; Jomaa, Hassan ; Kremsner, Peter G</creator><creatorcontrib>Missinou, Michel A ; Borrmann, Steffen ; Schindler, Andreas ; Issifou, Saadou ; Adegnika, Ayola A ; Matsiegui, Pierre-Blaise ; Binder, Ronald ; Lell, Bertrand ; Wiesner, Jochen ; Baranek, Thomas ; Jomaa, Hassan ; Kremsner, Peter G</creatorcontrib><description>Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(02)11860-5</identifier><identifier>PMID: 12493263</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adult ; Adults ; Animals ; Biological and medical sciences ; Clinical trials ; Drug Administration Schedule ; Drug resistance ; Drug therapy ; Female ; Fever ; Fosfomycin - administration & dosage ; Fosfomycin - adverse effects ; Fosfomycin - analogs & derivatives ; Fosfomycin - therapeutic use ; Fosmidomycin ; Gabon ; Human protozoal diseases ; Humans ; Infectious diseases ; Malaria ; Malaria, Falciparum - drug therapy ; Male ; Medical research ; Medical sciences ; Multidrug resistance ; Pain ; Parasites ; Parasitic diseases ; Patients ; Plasmodium falciparum ; Plasmodium falciparum - drug effects ; Protozoal diseases ; Schweitzer, Albert ; Treatment Outcome ; Tropical medicine ; Vector-borne diseases</subject><ispartof>The Lancet (British edition), 2002-12, Vol.360 (9349), p.1941-1942</ispartof><rights>2002 Elsevier Ltd</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Dec 14, 2002</rights><rights>Copyright Elsevier Limited Dec 14, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-25eaaa8126ca5497f50b42af20f45e584a2d9c330ec7e3d6e88acdddfb5bc8d43</citedby><cites>FETCH-LOGICAL-c446t-25eaaa8126ca5497f50b42af20f45e584a2d9c330ec7e3d6e88acdddfb5bc8d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673602118605$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14393786$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12493263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Missinou, Michel A</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><creatorcontrib>Schindler, Andreas</creatorcontrib><creatorcontrib>Issifou, Saadou</creatorcontrib><creatorcontrib>Adegnika, Ayola A</creatorcontrib><creatorcontrib>Matsiegui, Pierre-Blaise</creatorcontrib><creatorcontrib>Binder, Ronald</creatorcontrib><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Wiesner, Jochen</creatorcontrib><creatorcontrib>Baranek, Thomas</creatorcontrib><creatorcontrib>Jomaa, Hassan</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><title>Fosmidomycin for malaria</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.</description><subject>Adult</subject><subject>Adults</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Clinical trials</subject><subject>Drug Administration Schedule</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fever</subject><subject>Fosfomycin - administration & dosage</subject><subject>Fosfomycin - adverse effects</subject><subject>Fosfomycin - analogs & derivatives</subject><subject>Fosfomycin - therapeutic use</subject><subject>Fosmidomycin</subject><subject>Gabon</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Multidrug resistance</subject><subject>Pain</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Patients</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - drug effects</subject><subject>Protozoal diseases</subject><subject>Schweitzer, Albert</subject><subject>Treatment Outcome</subject><subject>Tropical medicine</subject><subject>Vector-borne diseases</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0D1LAzEYwPEgiq3V3UUpiqDDad4vmUSKVaHgoIJbyOUFUnp3NWmFfnvT9rCTOGX5PU-SPwBnCN4iiPjdG0QUFrwk_BriG4QEhwXbA31ES1owWn7ug_4v6YGjlKYQQsohOwQ9hKkkmJM-OB23qQ62rVcmNEPfxmGtZzoGfQwOvJ4ld9KdA_AxfnwfPReT16eX0cOkMJTyRYGZ01oLhLnRjMrSM1hRrD2GnjLHBNXYSkMIdKZ0xHInhDbWWl-xyghLyQBcbvfOY_u1dGmhpu0yNvlKhSGXEouSo6wu_lJICil4_kxGbItMbFOKzqt5DLWOK4WgWkdTm2hqXURBrDbRFMtz593yZVU7u5vqKmVw1QGdjJ75qBsT0s5RIkkpeHb3W-dysO_gokomuMY4G6IzC2Xb8M9TfgAi7IZJ</recordid><startdate>20021214</startdate><enddate>20021214</enddate><creator>Missinou, Michel A</creator><creator>Borrmann, Steffen</creator><creator>Schindler, Andreas</creator><creator>Issifou, Saadou</creator><creator>Adegnika, Ayola A</creator><creator>Matsiegui, Pierre-Blaise</creator><creator>Binder, Ronald</creator><creator>Lell, Bertrand</creator><creator>Wiesner, Jochen</creator><creator>Baranek, Thomas</creator><creator>Jomaa, Hassan</creator><creator>Kremsner, Peter G</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20021214</creationdate><title>Fosmidomycin for malaria</title><author>Missinou, Michel A ; Borrmann, Steffen ; Schindler, Andreas ; Issifou, Saadou ; Adegnika, Ayola A ; Matsiegui, Pierre-Blaise ; Binder, Ronald ; Lell, Bertrand ; Wiesner, Jochen ; Baranek, Thomas ; Jomaa, Hassan ; Kremsner, Peter G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-25eaaa8126ca5497f50b42af20f45e584a2d9c330ec7e3d6e88acdddfb5bc8d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Clinical trials</topic><topic>Drug Administration Schedule</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fever</topic><topic>Fosfomycin - administration & dosage</topic><topic>Fosfomycin - adverse effects</topic><topic>Fosfomycin - analogs & derivatives</topic><topic>Fosfomycin - therapeutic use</topic><topic>Fosmidomycin</topic><topic>Gabon</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Multidrug resistance</topic><topic>Pain</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Patients</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - drug effects</topic><topic>Protozoal diseases</topic><topic>Schweitzer, Albert</topic><topic>Treatment Outcome</topic><topic>Tropical medicine</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Missinou, Michel A</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><creatorcontrib>Schindler, Andreas</creatorcontrib><creatorcontrib>Issifou, Saadou</creatorcontrib><creatorcontrib>Adegnika, Ayola A</creatorcontrib><creatorcontrib>Matsiegui, Pierre-Blaise</creatorcontrib><creatorcontrib>Binder, Ronald</creatorcontrib><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Wiesner, Jochen</creatorcontrib><creatorcontrib>Baranek, Thomas</creatorcontrib><creatorcontrib>Jomaa, Hassan</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Missinou, Michel A</au><au>Borrmann, Steffen</au><au>Schindler, Andreas</au><au>Issifou, Saadou</au><au>Adegnika, Ayola A</au><au>Matsiegui, Pierre-Blaise</au><au>Binder, Ronald</au><au>Lell, Bertrand</au><au>Wiesner, Jochen</au><au>Baranek, Thomas</au><au>Jomaa, Hassan</au><au>Kremsner, Peter G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fosmidomycin for malaria</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2002-12-14</date><risdate>2002</risdate><volume>360</volume><issue>9349</issue><spage>1941</spage><epage>1942</epage><pages>1941-1942</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>12493263</pmid><doi>10.1016/S0140-6736(02)11860-5</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2002-12, Vol.360 (9349), p.1941-1942 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2069928761 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EBSCOhost Business Source Complete |
| subjects | Adult Adults Animals Biological and medical sciences Clinical trials Drug Administration Schedule Drug resistance Drug therapy Female Fever Fosfomycin - administration & dosage Fosfomycin - adverse effects Fosfomycin - analogs & derivatives Fosfomycin - therapeutic use Fosmidomycin Gabon Human protozoal diseases Humans Infectious diseases Malaria Malaria, Falciparum - drug therapy Male Medical research Medical sciences Multidrug resistance Pain Parasites Parasitic diseases Patients Plasmodium falciparum Plasmodium falciparum - drug effects Protozoal diseases Schweitzer, Albert Treatment Outcome Tropical medicine Vector-borne diseases |
| title | Fosmidomycin for malaria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fosmidomycin%20for%20malaria&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Missinou,%20Michel%20A&rft.date=2002-12-14&rft.volume=360&rft.issue=9349&rft.spage=1941&rft.epage=1942&rft.pages=1941-1942&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(02)11860-5&rft_dat=%3Cproquest_cross%3E2069928761%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198986263&rft_id=info:pmid/12493263&rft_els_id=S0140673602118605&rfr_iscdi=true |